RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay Inc. (AMEX:ISR) a medical isotope company focusing on the treatment of prostate and other malignant disease through use of its proprietary radioisotope technology, today announced its financial results for the first quarter ended September 30, 2008.
